Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Why Bluebird Bio Stock Is Sinking This Week
05:01pm, Thursday, 10'th Mar 2022
The unexpected departure of its CFO and an ominous note of caution rattled investors.
Wednesday''s top analyst upgrades and downgrades included Advanced Micro Devices, Bluebird Bio, Dollar Tree, Diamondback Energy, Fastenal, Kohl''s, Limelight Networks, Netflix, Palantir Technologies, PayPal, Southwestern Energy, S&P Global and Unity Software.
Tuesay''s top analyst upgrades and downgrades included AngloGold Ashanti, Ares Capital, Bank of America, Beyond Meat, Bluebird Bio, Coinbase Global, ConocoPhillips, Dell Technologies, Empire State Realty Trust, HollyFrontier, MicroVision, Next Era Energy, Okta and TAL Education.
bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes
10:41pm, Monday, 07'th Mar 2022 Zacks Investment Research
bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.
Why Bluebird Bio Stock Is Sinking Today
07:58pm, Monday, 07'th Mar 2022 The Motley Fool
The biotech's financial position has some investors worried.
Why Bluebird Bio Stock Is Sinking Today
07:58pm, Monday, 07'th Mar 2022 The Motley Fool
The biotech''s financial position has some investors worried.
Expert Ratings For bluebird bio
07:15pm, Monday, 07'th Mar 2022 Benzinga
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
0
1
3
0
Last 30
bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes
06:46pm, Monday, 07'th Mar 2022
bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022
03:03pm, Monday, 07'th Mar 2022 Benzinga
Upgrades
According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics showed an EPS of $1.09,
Why Bluebird Bio Stock Is Sinking Today
02:58pm, Monday, 07'th Mar 2022
The biotech's financial position has some investors worried.
Bluebird bio sinks as finance chief resigns
02:18pm, Monday, 07'th Mar 2022 Seeking Alpha
Vadzim Kushniarou/iStock via Getty Images Bluebird bio (NASDAQ:BLUE) is trading ~17% lower in the pre-market Monday after the commercial-stage biotech company announced the resignation of…
A Peek Into The Markets: US Stock Futures Tumble; Crude Oil Jumps Over 7%
10:24am, Monday, 07'th Mar 2022 Benzinga
Pre-open movers
U.S. stock futures traded lower in early pre-market trade amid escalating Russia-Ukraine concerns. Investors are awaiting earnings results from Ciena Corporation (NYSE: CIEN), Vermili
Why Bluebird Bio Shares Are Tumbling Today
10:19am, Monday, 07'th Mar 2022
Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of approximately $442 million. The full-year 2022 cash burn is ex
5 Stocks To Watch For March 7, 2022
09:13am, Monday, 07'th Mar 2022 Benzinga
Some of the stocks that may grab investor focus today are:
Wall Street expects Ciena Corporation (NYSE: CIEN) to report quarterly earnings at $0.45 per share on revenue of $856.85 million before th
bluebird bio Q4 2021 Earnings Preview (NASDAQ:BLUE)
10:35pm, Sunday, 06'th Mar 2022 Seeking Alpha
bluebird bio (NASDAQ:BLUE) is scheduled to announce Q4 earnings results on Monday, March 7th, after market close.The consensus EPS Estimate is -$1.74 (+42.2% Y/Y) and the consensus…
